×

BioTelemetry, Inc. Announces Retirement of Director Ronald A. Ahrens

MALVERN, Pa., Sept. 24, 2015 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced today that Board member Ronald A. Ahrens will retire after 7 years of service to BioTelemetry shareholders.

Mr. Ahrens joined BioTelemetry’s Board in 2008 and has served as Chairman of the Compensation Committee since 2009. Prior to joining BioTelemetry, Mr. Ahrens had extensive experience as a Director and Board consultant, most recently serving as Vice Chairman of Temptime Corporation from 2004 to 2013 and as Chairman of the Compensation Committee of VIASYS Healthcare Inc. from 2001 to 2007. Mr. Ahrens has over 40 years of management experience in the healthcare industry, having held various leadership positions with Merck & Co., including President of Merck Consumer Healthcare Group Worldwide and Executive Vice President of Merck Consumer Healthcare Group International. Mr. Ahrens received an undergraduate degree from Concordia College and a Masters in Sacred Theology from Concordia Seminary.

Joseph Capper, President and Chief Executive Officer of BioTelemetry, Inc., commented, “We are extremely appreciative of Mr. Ahrens’ service and contributions to our Company and our shareholders. The management team of BioTelemetry, as well as his fellow Board members, have benefitted greatly from his invaluable insight and counsel throughout his tenure. The Company’s sustained success over the past few years would not have happened without Ron’s expertise and passion for our vision. We are enormously grateful for his unwavering commitment and wish Ron a healthy, happy and long retirement.”

About BioTelemetry, Inc.
BioTelemetry, Inc., formerly known as CardioNet, Inc., is the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care. The Company currently provides cardiac monitoring services, original equipment manufacturing with a primary focus on cardiac monitoring devices and centralized cardiac core laboratory services. More information can be found at www.gobio.com.

BioTelemetry’s Cautionary Statement Regarding Forward-Looking Statements
This document includes certain forward-looking statements within the meaning of the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “expect,” “anticipate,” “estimate,” “intend,” “plan,” “believe,” “promises” and other words and terms of similar meaning. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including important factors that could delay, divert, or change any of these expectations, and could cause actual outcomes and results to differ materially from current expectations. These factors include, among other things, our ability to successfully integrate the Mednet, Biomedical Systems and Radcore businesses into our business and the effect such acquisitions will have on our results of operation, our ability to successfully finalize a settlement of the Department of Justice investigation, effectiveness of our cost savings initiatives, relationships with our government and commercial payors, changes to insurance coverage and reimbursement levels for our products, the success of our sales and marketing initiatives, our ability to attract and retain talented executive management and sales personnel, our ability to identify acquisition candidates, acquire them on attractive terms and integrate their operations into our business, the commercialization of new products, market factors, internal research and development initiatives, partnered research and development initiatives, competitive product development, changes in governmental regulations and legislation, the continued consolidation of payors, acceptance of our new products and services, patent protection, adverse regulatory action, and litigation success. For further details and a discussion of these and other risks and uncertainties, please see our public filings with the Securities and Exchange Commission, including our latest periodic reports on Form 10-K and 10-Q. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

BioTelemetry, Inc. Heather C. Getz Investor Relations 800-908-7103 investorrelations@biotelinc.com

Source:BioTelemetry, Inc.